Request Sample Inquiry
Parkinson’s Disease Treatment Market

Parkinson’s Disease Treatment Market

Parkinson’s Disease Treatment Market - Global Industry Assessment & Forecast

img
Healthcare
Number Of Pages # Pages:

215

Base Year:

2024

Date

Dec - 2024

Format:

PDF XLS PPT

Report Code:

VMR-3923

Segments Covered
  • By Drug Class By Drug Class Carbidopa-levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT inhibitors, Anticholinergics, Others
  • By Distribution Channel By Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2024
Forecast YearsForecast Years: 2025 - 2035
Historical YearsHistorical Years: 2019 - 2023
Revenue 2024Revenue 2024: USD 6.67 Billion
Revenue 2035Revenue 2035: USD 19.24 Billion
Revenue CAGRRevenue CAGR (2025 - 2035): 10.1%
Fastest Growing Region Fastest Growing Region (2025 - 2035) Asia Pacific
Largest Region Largest Region (2024): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Parkinson’s Disease Treatment Market - Segment Analysis
    1. Overview
    2. Global Parkinson’s Disease Treatment Market, 2016 - 2028 (USD Million)
    3. Global Parkinson’s Disease Treatment Market - by Drug Class
      1. By Carbidopa-levodopa
      2. By Dopamine Agonists
      3. By MAO-B Inhibitors
      4. By COMT inhibitors
      5. By Anticholinergics
      6. By Others
    4. Global Parkinson’s Disease Treatment Market - by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    5. Global Parkinson’s Disease Treatment Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    6. Market comparative analysis
  4. North America Parkinson’s Disease Treatment Market - Segment Analysis
    1. Overview
    2. North America Parkinson’s Disease Treatment Market, 2016 - 2028 (USD Million)
    3. North America Parkinson’s Disease Treatment Market, by Drug Class
      1. By Carbidopa-levodopa
      2. By Dopamine Agonists
      3. By MAO-B Inhibitors
      4. By COMT inhibitors
      5. By Anticholinergics
      6. By Others
    4. North America Parkinson’s Disease Treatment Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    5. North America Parkinson’s Disease Treatment Market, by Country
      1. U.S.
        1. U.S. Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. U.S. Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. Canada
        1. Canada Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Canada Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. Mexico
        1. Mexico Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Mexico Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  5. Europe Parkinson’s Disease Treatment Market - Segment Analysis
    1. Overview
    2. Europe Parkinson’s Disease Treatment Market, 2016 - 2028 (USD Million)
    3. Europe Parkinson’s Disease Treatment Market, by Drug Class
      1. By Carbidopa-levodopa
      2. By Dopamine Agonists
      3. By MAO-B Inhibitors
      4. By COMT inhibitors
      5. By Anticholinergics
      6. By Others
    4. Europe Parkinson’s Disease Treatment Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    5. Europe Parkinson’s Disease Treatment Market, by Country
      1. Germany
        1. Germany Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Germany Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. UK
        1. UK Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. UK Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. France
        1. France Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. France Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      4. Spain
        1. Spain Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Spain Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      5. Italy
        1. Italy Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Italy Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      6. BENELUX
        1. BENELUX Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. BENELUX Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      7. Rest of Europe
        1. Rest Of Europe Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Rest Of Europe Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  6. Asia Pacific Parkinson’s Disease Treatment Market - Segment Analysis
    1. Overview
    2. Asia Pacific Parkinson’s Disease Treatment Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Parkinson’s Disease Treatment Market, by Drug Class
      1. By Carbidopa-levodopa
      2. By Dopamine Agonists
      3. By MAO-B Inhibitors
      4. By COMT inhibitors
      5. By Anticholinergics
      6. By Others
    4. Asia Pacific Parkinson’s Disease Treatment Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    5. Asia Pacific Parkinson’s Disease Treatment Market, by Country
      1. China
        1. China Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. China Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. Japan
        1. Japan Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Japan Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. India
        1. India Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. India Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      4. South Korea
        1. South Korea Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. South Korea Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      5. South East Asia
        1. South East Asia Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. South East Asia Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Rest of Asia Pacific Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  7. Latin America Parkinson’s Disease Treatment Market - Segment Analysis
    1. Overview
    2. Latin America Parkinson’s Disease Treatment Market, 2016 - 2028 (USD Million)
    3. Latin America Parkinson’s Disease Treatment Market, by Drug Class
      1. By Carbidopa-levodopa
      2. By Dopamine Agonists
      3. By MAO-B Inhibitors
      4. By COMT inhibitors
      5. By Anticholinergics
      6. By Others
    4. Latin America Parkinson’s Disease Treatment Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    5. Latin America Parkinson’s Disease Treatment Market, by Country
      1. Brazil
        1. Brazil Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Brazil Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. Argentina
        1. Argentina Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Argentina Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. Rest of Latin America
        1. Rest of Latin America Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Rest of Latin America Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  8. Middle East & Africa Parkinson’s Disease Treatment Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Parkinson’s Disease Treatment Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Parkinson’s Disease Treatment Market, by Drug Class
      1. By Carbidopa-levodopa
      2. By Dopamine Agonists
      3. By MAO-B Inhibitors
      4. By COMT inhibitors
      5. By Anticholinergics
      6. By Others
    4. Middle East & Africa Parkinson’s Disease Treatment Market, by Distribution Channel
      1. By Hospital Pharmacy
      2. By Retail Pharmacy
      3. By Online Pharmacy
    5. Middle East & Africa Parkinson’s Disease Treatment Market, by Country
      1. GCC Countries
        1. GCC Countries Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. GCC Countries Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      2. South Africa
        1. South Africa Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. South Africa Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Parkinson’s Disease Treatment Market, By Drug Class
          1. By Carbidopa-levodopa
          2. By Dopamine Agonists
          3. By MAO-B Inhibitors
          4. By COMT inhibitors
          5. By Anticholinergics
          6. By Others
        2. Rest of Middle East & Africa Parkinson’s Disease Treatment Market, By Distribution Channel
          1. By Hospital Pharmacy
          2. By Retail Pharmacy
          3. By Online Pharmacy
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Cerevel Therapeutics
    2. Novartis AG
    3. Teva Pharmaceutical Industries Ltd.
    4. Merck & Co. Inc.
    5. GlaxoSmithKline plc. (GSK)
    6. AbbVie Inc.
    7. H. Lundbeck A/S
    8. Amneal Pharmaceuticals LLC
    9. Supernus Pharmaceuticals Inc.
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 16-Jan-2025
Parkinson’s Disease Treatment Market to Reach USD 19.24 Billion by 2035
FAQ
Frequently Asked Question

  • The global Parkinson’s Disease Treatment valued at USD 6.67 Billion in 2024 and is expected to reach USD 19.24 Billion in 2035 growing at a CAGR of 10.1%.

  • The prominent players in the market are Cerevel Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc. (GSK), AbbVie Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, Supernus Pharmaceuticals Inc..

  • The market is project to grow at a CAGR of 10.1% between 2025 and 2035.

  • The driving factors of the Parkinson’s Disease Treatment include

  • North America was the leading regional segment of the Parkinson’s Disease Treatment in 2024.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy